Rare Diseases
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
Showing 1–12 of 31 articles
Quick answer
NovaPharmaNews Rare Diseases hub for EMA covers 31 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Federal Court Litigation on Reproductive Health: Rare Disease Implications
EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma
FDA Voucher Program Pause Urged: Rare Disease Policy Analysis
Japan Grants Orphan Status to QRX003 for Netherton Syndrome: Implications for Pharma Teams
CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams
X4 Pharmaceuticals Secures Positive EMA CHMP Opinion for Mavorixafor in WHIM Syndrome
Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
Stoke Therapeutics Zorevunersen Shows Promise for Dravet Syndrome Treatment Ahead of Q1 2026 Results
HUTCHMED's Sovleplenib Receives Priority Review and Breakthrough Designation in China for Rare Blood Disorder
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.